Iqvia (NYSE:IQV) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a report released on Tuesday.
IQV has been the topic of several other reports. KeyCorp reaffirmed a “sector weight” rating and set a $100.00 price objective on shares of Iqvia in a report on Friday, November 10th. Zacks Investment Research upgraded Iqvia from a “hold” rating to a “buy” rating and set a $112.00 price target on the stock in a report on Thursday, January 18th. Mizuho lowered Iqvia from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Thursday, November 9th. SunTrust Banks restated a “hold” rating and set a $110.00 price target on shares of Iqvia in a report on Monday, January 22nd. Finally, Mitsubishi UFJ Financial Group assumed coverage on Iqvia in a report on Friday, December 15th. They set a “neutral” rating and a $112.00 price target on the stock. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $110.02.
Shares of Iqvia (NYSE:IQV) traded down $1.46 on Tuesday, hitting $100.26. The stock had a trading volume of 1,301,499 shares, compared to its average volume of 1,200,000. The stock has a market cap of $20,850.00, a PE ratio of 66.84, a price-to-earnings-growth ratio of 1.81 and a beta of 0.61. Iqvia has a twelve month low of $75.94 and a twelve month high of $110.67. The company has a quick ratio of 1.22, a current ratio of 1.19 and a debt-to-equity ratio of 1.21.
In other Iqvia news, insider James H. Erlinger III sold 10,000 shares of the company’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $99.97, for a total value of $999,700.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John Connaughton sold 1,163,191 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $102.00, for a total value of $118,645,482.00. The disclosure for this sale can be found here. Insiders sold a total of 8,727,078 shares of company stock worth $890,124,079 in the last ninety days. 6.40% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in IQV. Winslow Evans & Crocker Inc. bought a new position in Iqvia in the 4th quarter valued at $123,000. Focused Wealth Management Inc bought a new position in Iqvia in the 4th quarter valued at $166,000. Valeo Financial Advisors LLC bought a new position in shares of Iqvia during the 4th quarter worth $170,000. IFP Advisors Inc bought a new position in shares of Iqvia during the 4th quarter worth $200,000. Finally, Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Iqvia during the 4th quarter worth $209,000. 96.09% of the stock is currently owned by institutional investors.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.